Harbor MedTech
Private Company
Funding information not available
Overview
Harbor MedTech is a privately held, commercial-stage company developing regenerative medicine solutions for soft tissue repair. Its core asset is the BriDGE® technology, a proprietary collagen processing method that creates a matrix shown in studies to accelerate healing, support regeneration, and exhibit antimicrobial properties. The company currently has two FDA-cleared and CE-marked products and is advancing a pipeline targeting sports medicine, hernia/breast reconstruction, and chronic wounds. Harbor MedTech operates as a fully integrated entity, positioning itself to capture value in the growing orthopedic biologics and advanced wound care markets.
Technology Platform
BriDGE® (Bio-friendly Regenerative & Guided Engineering) technology: a patented method to process intact Type-1 collagen into a stabilized, acellular matrix that recruits host growth factors, supports tissue regeneration, and exhibits antimicrobial properties to activate the patient's own healing cascade.
Opportunities
Risk Factors
Competitive Landscape
Harbor MedTech competes in the crowded orthopedic biologics and advanced wound care markets against giants like Johnson & Johnson (DePuy Synthes), Smith & Nephew (Regeneten), Integra LifeSciences, and Organogenesis. Its differentiation hinges on the unique combination of properties offered by the BriDGE® matrix: slow degradation, growth factor recruitment, and inherent antimicrobial support.